Wilate

Wilate is a human coagulation factor VIII and von Willebrand factor complex used for bleeding disorders. This intravenous therapy supports hemostasis in conditions like von Willebrand disease and hemophilia A. Suitable for patients requiring factor replacement. Always consult a healthcare provider for personalized use.

Wilate is used to prevent and control bleeding episodes in patients with von Willebrand disease and hemophilia A. It works by replacing missing or deficient clotting factors in the blood. This therapy is particularly helpful during surgeries or dental procedures where bleeding risk is elevated. It may also be used for routine prophylaxis to reduce bleeding frequency.

After administration, Wilate helps restore normal clotting function by increasing factor VIII and von Willebrand factor levels in the bloodstream. Patients may experience improved bleeding control within hours of infusion. Regular use can reduce the frequency and severity of spontaneous bleeding episodes over time.

Wilate should be stored properly to maintain its effectiveness; check the product leaflet for temperature requirements. Always use sterile techniques during preparation and administration to prevent contamination. Patients should report any signs of allergic reactions or unusual symptoms immediately to their healthcare provider.

Wilate may interact with other medications that affect blood clotting, such as anticoagulants or antiplatelet drugs. Patients should inform their healthcare provider about all medications they are taking before starting Wilate therapy. No specific drug interactions are widely documented, but caution is advised when combining with other hemostatic agents.